- |||||||||| lamotrigine IV / CURx Pharma
Clinical, Journal, Adverse events: Reverse translational analysis of clinically reported, lamotrigine-induced cardiovascular adverse events using the halothane-anesthetized dogs. (Pubmed Central) - Jul 16, 2021
Lamotrigine was intravenously administered in doses of 0.1, 1 and 10 mg/kg/10 min under the monitoring of cardiovascular variables, possibly providing subtherapeutic to supratherapeutic plasma concentrations...This finding may partly explain the onset mechanism of lamotrigine-associated cardiac adverse events in the clinical cases. In addition, elevation of J wave was induced in half of the animals, suggesting that lamotrigine may have some potential to unmask Brugada electrocardiographic genotype in susceptible patients.
- |||||||||| Trileptal (oxcarbazepine) / Novartis
[VIRTUAL] Sphenopalatine Ganglion Block for the Treatment of SUNCT Syndrome in a Geriatric Patient () - Jul 15, 2020 - Abstract #AHS2020AHS_262;
Patients with SUNCT can often be refractory to standard headache medications, and side effects from medications, drug interactions, and tolerability can be a limiting factor in the choice of oral treatments for elderly patients. SPG block is a safe, office-based, and non-invasive procedure that can be considered for treatment of pain in elderly patients with SUNCT.
|
